Possible Role of Interaction between PPARα and Cyclophilin D in Cardioprotection of AMPK against In Vivo Ischemia-Reperfusion in Rats

Activated AMPK protects the heart from cardiac ischemia-reperfusion (IR) injury and is associated with inhibition of mitochondrial permeability transition pore (PTP) opening. On the other hand, pharmacological inhibition of the PTP reduces infarct size and improves cardiac function. However, it is u...

Full description

Saved in:
Bibliographic Details
Main Authors: Giselle Barreto-Torres, Sabzali Javadov
Format: Article
Language:English
Published: Wiley 2016-01-01
Series:PPAR Research
Online Access:http://dx.doi.org/10.1155/2016/9282087
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832553440446775296
author Giselle Barreto-Torres
Sabzali Javadov
author_facet Giselle Barreto-Torres
Sabzali Javadov
author_sort Giselle Barreto-Torres
collection DOAJ
description Activated AMPK protects the heart from cardiac ischemia-reperfusion (IR) injury and is associated with inhibition of mitochondrial permeability transition pore (PTP) opening. On the other hand, pharmacological inhibition of the PTP reduces infarct size and improves cardiac function. However, it is unclear whether beneficial effects of AMPK are mediated through the PTP and, if they are not, whether simultaneous activation of AMPK and inhibition of the PTP exert synergistic protective effects against cardiac IR injury. Here, we examined the effects of the AMPK activator, A-769662 in combination with the PTP inhibitor, sanglifehrin A (SfA) on in vivo cardiac IR. Cardiac dysfunction following IR injury was associated with decreased activity of the mitochondrial electron transport chain (ETC) and increased mitochondrial ROS and PTP opening. Administration of A-769662 or SfA individually upon reperfusion improved cardiac function, reduced infarction size, and inhibited ROS production and PTP opening. However, simultaneous administration of SfA and A-769662 did not provide synergistic improvement of postischemic recovery of cardiac and mitochondrial function, though both compounds disrupted IR-induced interaction between PPARα and CyP-D. In conclusion, A-769662 or SfA prevents PPARα interaction with CyP-D, improving cardiac outcomes and increasing mitochondrial function, and simultaneous administration of the drugs does not provide synergistic effects.
format Article
id doaj-art-fb8fa42a474a49ebb285e8885d1fc9bd
institution Kabale University
issn 1687-4757
1687-4765
language English
publishDate 2016-01-01
publisher Wiley
record_format Article
series PPAR Research
spelling doaj-art-fb8fa42a474a49ebb285e8885d1fc9bd2025-02-03T05:54:04ZengWileyPPAR Research1687-47571687-47652016-01-01201610.1155/2016/92820879282087Possible Role of Interaction between PPARα and Cyclophilin D in Cardioprotection of AMPK against In Vivo Ischemia-Reperfusion in RatsGiselle Barreto-Torres0Sabzali Javadov1Department of Physiology, University of Puerto Rico School of Medicine, San Juan, PR 00936-5067, USADepartment of Physiology, University of Puerto Rico School of Medicine, San Juan, PR 00936-5067, USAActivated AMPK protects the heart from cardiac ischemia-reperfusion (IR) injury and is associated with inhibition of mitochondrial permeability transition pore (PTP) opening. On the other hand, pharmacological inhibition of the PTP reduces infarct size and improves cardiac function. However, it is unclear whether beneficial effects of AMPK are mediated through the PTP and, if they are not, whether simultaneous activation of AMPK and inhibition of the PTP exert synergistic protective effects against cardiac IR injury. Here, we examined the effects of the AMPK activator, A-769662 in combination with the PTP inhibitor, sanglifehrin A (SfA) on in vivo cardiac IR. Cardiac dysfunction following IR injury was associated with decreased activity of the mitochondrial electron transport chain (ETC) and increased mitochondrial ROS and PTP opening. Administration of A-769662 or SfA individually upon reperfusion improved cardiac function, reduced infarction size, and inhibited ROS production and PTP opening. However, simultaneous administration of SfA and A-769662 did not provide synergistic improvement of postischemic recovery of cardiac and mitochondrial function, though both compounds disrupted IR-induced interaction between PPARα and CyP-D. In conclusion, A-769662 or SfA prevents PPARα interaction with CyP-D, improving cardiac outcomes and increasing mitochondrial function, and simultaneous administration of the drugs does not provide synergistic effects.http://dx.doi.org/10.1155/2016/9282087
spellingShingle Giselle Barreto-Torres
Sabzali Javadov
Possible Role of Interaction between PPARα and Cyclophilin D in Cardioprotection of AMPK against In Vivo Ischemia-Reperfusion in Rats
PPAR Research
title Possible Role of Interaction between PPARα and Cyclophilin D in Cardioprotection of AMPK against In Vivo Ischemia-Reperfusion in Rats
title_full Possible Role of Interaction between PPARα and Cyclophilin D in Cardioprotection of AMPK against In Vivo Ischemia-Reperfusion in Rats
title_fullStr Possible Role of Interaction between PPARα and Cyclophilin D in Cardioprotection of AMPK against In Vivo Ischemia-Reperfusion in Rats
title_full_unstemmed Possible Role of Interaction between PPARα and Cyclophilin D in Cardioprotection of AMPK against In Vivo Ischemia-Reperfusion in Rats
title_short Possible Role of Interaction between PPARα and Cyclophilin D in Cardioprotection of AMPK against In Vivo Ischemia-Reperfusion in Rats
title_sort possible role of interaction between pparα and cyclophilin d in cardioprotection of ampk against in vivo ischemia reperfusion in rats
url http://dx.doi.org/10.1155/2016/9282087
work_keys_str_mv AT gisellebarretotorres possibleroleofinteractionbetweenpparaandcyclophilindincardioprotectionofampkagainstinvivoischemiareperfusioninrats
AT sabzalijavadov possibleroleofinteractionbetweenpparaandcyclophilindincardioprotectionofampkagainstinvivoischemiareperfusioninrats